(MARCH 15, 2017) Clostridium difficile, commonly known as C. diff, affects nearly half a million Americans a year, and leads to several thousand fatalities, according to the CDC. This infection is difficult to treat, especially among those with an antibiotic-resistant strain, but Peter Moses, M.D., professor of medicine at the Larner College of Medicine and gastroenterologist at the UVM Medical Center, uses fecal microbiota transplantation (FMT) as a solution.
Peter Moses, M.D., professor of medicine at the Larner College of Medicine and gastroenterologist at the UVM Medical Center (Photo: LCOM Creative Services)
(MARCH 15, 2017) Clostridium difficile, commonly known as C. diff, affects nearly half a million Americans a year, and leads to several thousand fatalities, according to the CDC. This infection is difficult to treat, especially among those with an antibiotic-resistant strain, but Peter Moses, M.D., professor of medicine at the Larner College of Medicine and gastroenterologist at the UVM Medical Center, uses fecal microbiota transplantation (FMT) as a solution. With a 90% success rate in curing C. diff in his patients, Dr. Moses is now setting his sights on using this procedure to cure other gastrointestinal and autoimmune disorders. Read more about his study in
Seven Days.